CAR-T Therapy in China 2026: 7 Approved Products at 1/5 the Cost
China now has more approved CAR-T therapies than any country except the US — including the world's first solid-tumor CAR-T (satri-cel, approved June 2026). Prices are $30,000-$80,000, compared to $300,000-$500,000 in the US and Singapore. We help international patients access China's leading CAR-T hospitals.
Why China for CAR-T Therapy?
China has emerged as a global powerhouse in CAR-T cell therapy for three reasons:
- More products, faster: 7 approved CAR-T therapies as of June 2026 vs 6 in the US — including satri-cel, the world's first CAR-T approved for solid tumors (gastric cancer).
- 1/5 the cost: Chinese CAR-T therapies are priced $30,000-$80,000 per treatment vs $300,000-$500,000 in the US and $200,000-$400,000 in Singapore. Some hospitals offer compassionate-use pricing even lower.
- High-volume centers: Chinese hospitals administer more CAR-T treatments annually than most Western centers, giving clinical teams extensive real-world experience managing cytokine release syndrome (CRS) and neurotoxicity.
Cost Comparison: CAR-T in China vs US vs Singapore
Includes hospital stay + monitoring
Excludes hospitalization
Often requires referral
* Prices are estimates based on published data and patient reports as of 2026. Final cost depends on specific product, hospital, and clinical complexity.
7 Approved CAR-T Products in China (2026)
| Product | Target | Indication | Approved |
|---|---|---|---|
| Yescarta (Axicabtagene ciloleucel) | CD19 | Large B-cell lymphoma | 2021 |
| Carteyva (Relmacabtagene autoleucel) | CD19 | Large B-cell lymphoma | 2021 |
| CNCT19 (Inaticabtagene autoleucel) | CD19 | B-cell ALL | 2023 |
| Equecabtagene autoleucel | BCMA | Multiple myeloma | 2023 |
| Zevorcabtagene autoleucel | BCMA | Multiple myeloma | 2024 |
| Limenca-Cel | CD19 | Leukemia/Lymphoma | 2025 |
| Satri-cel ☆ | CLDN18.2 | Solid tumors (gastric) | June 2026 |
☆ Satri-cel is the world's first approved CAR-T for solid tumors — a historic milestone in cancer immunotherapy.
Top CAR-T Hospitals in China
Peking University Cancer Hospital (Beijing)
Leader in CAR-T clinical trials. International patient department. English-speaking oncology team.
Fudan University Shanghai Cancer Center
One of Asia's largest cancer centers. Active in CAR-T research and treatment protocols.
Sun Yat-sen University Cancer Center (Guangzhou)
Major center for hematologic malignancies. CAR-T treatment since 2021. Southeast Asian patient focus.
Ruijin Hospital (Shanghai)
Administered China's first commercial CAR-T. Strong hematology department with international services.
Tongji Hospital (Wuhan)
Growing CAR-T program with competitive pricing. International department available.
West China Hospital (Chengdu)
Western China's premier medical center. Active CAR-T program with international patient coordination.
How to Start CAR-T Treatment in China
Send us your diagnosis, treatment history, and recent reports. Free, no commitment.
We identify 2-3 hospitals with active CAR-T programs matching your cancer type and budget.
Hospital contact, record translation, appointment setup, visa guidance, and airport pickup.
Frequently Asked Questions
Am I eligible for CAR-T therapy in China?
CAR-T is primarily indicated for certain blood cancers (lymphoma, leukemia, multiple myeloma) and, starting 2026, CLDN18.2-positive gastric cancer. Eligibility depends on your specific diagnosis, prior treatments, and overall health. We help you determine if CAR-T could be an option by connecting your records with treating hospitals.
How long do I need to stay in China for CAR-T treatment?
CAR-T is a multi-week process: approximately 1 week for pre-treatment evaluation and T-cell collection, 2-3 weeks for cell manufacturing, 1 week for infusion and initial monitoring, and 1-2 weeks for recovery observation. Plan for 4-6 weeks total in China.
Is CAR-T in China as effective as in the US?
Clinical outcomes for approved CAR-T products in China are comparable to international results. Chinese CAR-T centers follow the same protocols and monitoring standards as US and European centers. Many products are manufactured in China under GMP standards equivalent to international requirements.
Can I combine CAR-T with other treatments in China?
Yes. Many patients combine CAR-T with other therapies available in China, including targeted therapy, immunotherapy (checkpoint inhibitors), and Traditional Chinese Medicine for supportive care. Your treatment plan is determined by the hospital based on your specific case.
Ready to explore CAR-T treatment in China?
Start with a free case review. We'll match you with the right CAR-T center and help you understand costs, eligibility, and next steps — no commitment, no pressure.